CN114478566B - 消除冬凌草甲素1位羟基的衍生物及用途 - Google Patents
消除冬凌草甲素1位羟基的衍生物及用途 Download PDFInfo
- Publication number
- CN114478566B CN114478566B CN202210083027.6A CN202210083027A CN114478566B CN 114478566 B CN114478566 B CN 114478566B CN 202210083027 A CN202210083027 A CN 202210083027A CN 114478566 B CN114478566 B CN 114478566B
- Authority
- CN
- China
- Prior art keywords
- oridonin
- compound
- cdcl
- nmr
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Thermal Transfer Or Thermal Recording In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了消除冬凌草甲素1位羟基的衍生物及用途,结构如下,本发明通过对冬凌草甲素进行进一步结构修饰改造,提供一类具有抗三阴乳腺癌活性的新化合物。与冬凌草甲素相比,本发明的化合物不仅能很好的抑制三阴乳腺癌细胞生长,且具有更好的选择性,更低的毒性。
Description
技术领域
本发明涉及天然药物及药物化学领域,特别涉及一类新型的消除冬凌草甲素1位羟基的衍生物。
背景技术
乳腺癌的发病率逐年增高,是当今女性最常见的恶性肿瘤之一。而三阴乳腺癌(triple-negative breast cancer)是乳腺癌的一种特殊类型,约占乳腺癌的15%~17%。由于三阴乳腺癌不但有侵袭性强、复发早、进展快、生存短等特征,并且由于三阴乳腺癌患者的预后比较差,且目前临床尚缺乏对三阴乳腺癌具有良好治疗效果的药物,故提高三阴乳腺癌的患者生活质量并且降低死亡率已经刻不容缓(杜娟,等.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):5)。
冬凌草甲素(Oridonin)是一种从唇形科(Labtea)香茶菜属(Rabdosia)植物Isodon (Rabdosia rubescens)中分离得到一种贝壳杉烯二菇类天然有机化合物,是冬凌草的主要活性成分,具有清热解毒,活血化瘀,抗菌消炎,抗肿瘤等功效(赵永星等.冬凌草甲素纳米粒制备及其体外抗肿瘤活性[J].中国医院药学杂志,2008,28(11):864-867;刘晨江等.冬凌草甲素的抗肿瘤作用[J].中国药学杂志,1998,33:577)。前期的研究显示冬凌草甲素具有一定的抗三阴乳腺癌的活性(Journal of Medicinal Chemistry,2017,60,1449-1468),是研发抗三阴性乳腺癌的优良先导分子。但冬凌草甲素抗三阴乳腺癌的活性中等,限制了其进一步的临床应用,本专利拟对冬凌草甲素进行进一步结构修饰,以提供活性更优的冬凌草甲素衍生物。
发明内容
发明目的:本发明目的是提供一种消除冬凌草甲素1位羟基的衍生物,及其光学活性体或消旋体、非对应异构体混合物,或其可药用盐。
本发明另一目的是提供所述消除冬凌草甲素1位羟基的衍生物,及其光学活性体或消旋体、非对应异构体混合物,或其可药用盐的制药用途。
技术方案:本发明所述的的冬凌草甲素衍生物,及其光学活性体或消旋体、非对应异构体混合物,或其可药用盐:结构如下:
L选自-(CH2)m-、-(CH=CH)n-、-C≡C-、-CH2-O-CH2-、-CH2-S-CH2-、-CH2-NH-CH2-、-(CH2)m-Ar-(CH2)n-。
m为1,2,3,4,5,6;n为1,2。
R为5-10个原子组成的杂芳基、C3-C7环烷基、C3-C7环烯基、5-10个原子组成杂环烷基;
其中,所述杂芳基、C3-C7环烷基、C3-C7环烯基和杂环烷基各自任选地被选自下组的1、2、3、4个取代基取代:卤素、氨基、C1-C6烷基氨基、二(C1-C6烷基)氨基、硝基、氰基、羟基、羧基、C1-C6烷氧基、C1-C6卤代烷氧基、疏基、C1-C6烷硫基、C2-C6烯基、C2-C8炔基、C1-C6烷基、羟基C1-C6烷基和C1-C6卤代烷基。
进一步地,L优选为-(CH2)m-、-(CH=CH)n-;m,n优选为1,2,3。R优选为未被取代或被1、2、3、4个取代基所取代的5-10个原子组成的杂芳基。
进一步地,L优选为-CH2CH2-、-CH2CH2CH2-、-CH=CH-;R优选为未被取代或被1、2、3、4个取代基所取代的吡啶,吲哚,喹啉以及未被取代或被1、2、3个取代基所取代的嘧啶,呋喃,噻吩,吡咯,1,3-苯并间二氧杂环戊烯。
代表性的冬凌草甲素衍生物其部分化合物的结构如下:
本发明还提供一种药物组合物,其含有治疗有效量的一种或多种所述的消除冬凌草甲素1位羟基的衍生物,及其光学活性体或消旋体、非对应异构体混合物,或其可药用盐及药学上可接受的载体或辅料。
有益效果:本发明与现有技术相比,具有如下优势:
本发明通过对冬凌草甲素进行进一步结构修饰改造,提供一类具有抗三阴乳腺癌活性的新化合物。与冬凌草甲素相比,本发明的化合物不仅能很好的抑制三阴乳腺癌细胞生长,且具有更好的选择性,更低的毒性。
具体实施方式
实施例1
【化合物1】
将冬凌草甲素(2g,5.49mmol)溶解在无水丙酮(30mL)中。向该溶液中加入对甲苯磺酸和3mL 2,2-二甲氧基丙烷。将混合物在56℃搅拌30分钟,然后用水稀释,并用二氯甲烷萃取。萃取物用饱和碳酸氢钠溶液和盐水洗涤,用无水硫酸钠干燥,过滤并蒸发,得到白色粉末状固体2.10g,随后在0℃下将3mL三乙胺加入到该粉末状固体在20mL无水二氯甲烷中的溶液中。在1小时内将甲基磺酰氯(2mL)滴加到溶液中,然后将混合物再搅拌1小时。将混合物用水淬灭,用二氯甲烷萃取,用无水硫酸钠干燥,过滤,蒸发得到粗产物,将其通过柱色谱纯化(MeOH/CH2Cl2 1∶100,v/v)得到纯中间体1(2.01g,80%),为白色固体。
将碳酸锂(3.08g,41.65mmol)和溴化锂(3.62g,41.65mmol)加入到中间体1(2.01g,4.17mmol)在20mL无水二甲基甲酰胺(DMF)中的溶液中。将混合物在110℃剧烈搅拌1小时,然后冷却至室温。在滤出无机沉淀物后,将反应混合物用150mL二氯甲烷稀释,然后用水(20mL×3)和盐水(20mL×3)洗涤。有机层经无水硫酸钠干燥,过滤,蒸发得到粗产物,将其通过柱色谱法使用二氯甲烷纯化,得到纯中间体2(1.21g,75%)。
将中间体2(1.21g,3.13mmol)加入20mL 10%HCl/THF(1∶1)中,溶液在室温下搅拌1h。然后将混合物用水稀释并用二氯甲烷萃取。萃取物用盐水洗涤,经无水硫酸钠干燥,过滤并蒸发,得到中间体2(0.98g,90%),为白色粉末。
将中间体3(0.086mmol)和3-吡啶-4-基-丙酸(0.129mmol)溶解在无水二氯甲烷(10mL)、0.16mmol 1-(3-(二甲基氨基)丙基)-3-乙基碳二亚胺盐酸盐(EDCI)和催化量的DMAP中加入。将溶液在室温下搅拌直至中间体3消失。然后将该溶液用饱和碳酸氢钠水溶液稀释,并用乙酸乙酯萃取3次。合并的有机相用盐水洗涤,用无水硫酸钠干燥,真空浓缩。将残余物进行柱层析(硅胶,乙酸乙酯/石油醚,1∶8),得到化合物1(86%产率)。1H NMR(300MHz,CDCl3):δ7.23-7.02(m,4H),6.07(s,1H),5.85(s,1H),5.70(m,1H),5.57(d,J=11.5Hz,1H),5.45(s,1H),5.14(m,1H),4.15(s,1H),3.93(d,J=10.2Hz,1H),3.86-3.61(m,2H),2.93(d,J=9.4Hz,1H),2.84(t,J=7.4Hz,2H),2.56-2.45(m,3H),1.88-1.76(m,3H),1.55(s,1H),1.46(d,J=8.3Hz,1H),1.15(s,2H),1.06(s,3H),0.91(s,3H);13C NMR(75MHz,CDCl3):δ206.3,173.1,150.7133.2,126.3,125.3,127.4,125.5,123.1,97.3,76.1,74.2,67.1,63.4,59.3,54.3,42.8,41.6,39.6,37.7,34.5,32.3,31.6,30.8,28.9,23.5,16.7.HR-MS(ESI)m/z:calcd for C29H35O6[M+H]+480.2341,found 480.2343.
实施例2
【化合物2】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3):δ7.27-7.25(m,2H),7.27-7.04(m,2H),6.17(s,1H),5.89(s,1H),5.82(m,,1H),5.56(s,1H),5.23(dd,J=10.2,2.3Hz,1H),3.95(dd,J=30.5,10.3Hz,3H),3.85(d,J=8.3Hz,1H),3.16(d,J=9.7Hz,1H),2.65(t,J=7.5Hz,3H),2.30-2.25(m,2H),2.05-1.85(m,6H),1.83(d,J=6.1Hz,1H),1.65(dd,J=13.2,9.2Hz,2H),1.53(d,J=8.2Hz,1H),1.16(d,J=7.9Hz,3H),1.06(s,3H);13CNMR(75MHz,CDCl3):δ206.2,165.3,150.4,142.7,124.1,122.4,121.9,121.5,96.5,75.2,73.7,65.4,61.9,57.9,53.3,41.5,40.9,38.5,32.3,30.7,30.3,21.6,17.9.HR-MS(ESI)m/z:calcd for C30H36O6[M+H]+494.2498,found494.2495.
实施例3
【化合物3】
参照实施例1中化合物1的合成方法。1H NMR(500MHz,CDCl3)δ8.62-8.57(m,2H),7.56(dd,J=16.0,0.9Hz,1H),7.42-7.37(m,2H),6.51(d,J=15.9Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H)13C NMR(75MHz,CDCl3)δ208.06,167.16,151.40,150.30,145.69,141.70,134.41,127.38,122.55,118.55,117.68,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H32NO6[M+H]+478.2224,found 478.2230.
实施例4
【化合物4】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.77(t,J=2.0Hz,1H),8.54(ddd,J=3.9,2.2,1.5Hz,1H),7.98-7.92(m,1H),7.62(d,J=17.0Hz,1H),7.38(dd,J=7.8,3.8Hz,1H),6.41(d,J=16.9Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.75(m,3H),1.76(s,1H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCL3)δ208.06,167.29,151.68,151.40,149.30,143.00,134.43,134.41,130.06,127.38,124.24,118.55,117.61,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H32NO6[M+H]+478.2224,found 478.2230.
实施例5
【化合物5】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.59(dd,J=4.2,1.6Hz,1H),7.77-7.67(m,2H),7.54-7.48(m,1H),7.17(ddd,J=7.0,4.3,1.4Hz,1H),6.83(d,J=16.5Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,167.05,152.58,151.40,149.69,142.41,136.80,134.41,127.38,123.29,122.88,120.45,118.55,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H32NO6[M+H]+478.2224,found478.2230.
实施例6
【化合物6】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ7.59(t,J=1.4Hz,1H),7.47-7.40(m,1H),6.76-6.71(m,1H),6.55(dd,J=5.0,1.2Hz,1H),6.31(d,J=16.5Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,166.48,151.41,143.99,134.41,131.06,127.38,118.55,117.09,115.96,112.28,99.28,77.58,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C27H31O7[M+H]+467.2064,found 467.2067.
实施例7
【化合物7】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ9.70(d,J=6.8Hz,1H),7.52-7.46(m,1H),7.07(ddd,J=6.8,3.2,1.7Hz,1H),6.83-6.77(m,1H),6.54(d,J=15.6Hz,1H),6.24(dd,J=6.6,3.1Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13CNMR(75MHz,CDCl3)δ208.06,165.88,151.40,134.41,133.40,131.89,127.38,123.26,118.55,117.62,115.67,108.98,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C27H32NO6[M+H]+466.2224,found 466.2232.
实施例8
【化合物8】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ7.63-7.55(m,2H),7.50(dd,J=5.3,1.6Hz,1H),7.27-7.22(m,1H),6.38(d,J=16.0Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.63(m,1H),1.09(d,J=11.4Hz,5H).;13C NMR(75MHz,CDCl3)δ208.06,165.79,151.40,141.64,134.75,134.41,128.37,127.74,127.38,126.93,118.55,117.42,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,33.00,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C27H31O6S[M+H]+483.1836,found 483.1843.
实施例9
【化合物9】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.84(dd,J=5.7,1.8Hz,3H),7.67(d,J=17.2Hz,1H),6.42(d,J=17.2Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.63(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,167.41,158.37,154.81,151.40,142.63,134.41,127.38,118.75,118.55,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C27H31N2O6[M+H]+479.2177,found 479.2180.
实施例10
【化合物10】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ7.97(t,J=2.0Hz,1H),7.98-7.91(m,1H),7.91-7.83(m,2H),7.64(dd,J=8.4,1.9Hz,1H),7.55-7.48(m,2H),6.35(d,J=16.1Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.75(m,3H),1.76(s,1H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,167.10,146.24,134.70,134.41,134.20,131.69,130.11,128.48,128.12,128.11,127.64,127.38,126.74,126.62,118.55,116.60,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C33H35O6[M+H]+528.2341,found 528.2350.
实施例11
【化合物11】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ9.09(d,J=6.6Hz,1H),7.92-7.85(m,1H),7.52-7.46(m,1H),7.42(dd,J=7.8,1.5Hz,1H),7.34(t,J=7.8Hz,1H),7.26(dd,J=6.6,3.5Hz,1H),6.85(d,J=3.6Hz,1H),6.37(d,J=16.7Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.84-1.75(m,3H),1.76(s,1H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,167.25,151.40,136.17,135.86,134.41,130.39,127.63,127.38,125.86,123.15,122.39,118.86,118.55,113.61,101.07,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C31H34NO6[M+H]+516.2381,found 516.2386.
实施例12
【化合物12】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ7.80-7.73(m,1H),7.27(dd,J=8.0,1.5Hz,1H),7.02(t,J=7.9Hz,1H),6.92(dd,J=7.7,1.5Hz,1H),6.49(d,J=16.5Hz,1H),6.06-5.91(m,3H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.93(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.63(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,166.91,151.40,148.78,146.35,139.71,134.41,127.38,123.14,121.52,121.16,118.55,118.22,110.88,101.80,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C30H33O8[M+H]+521.2170,found 521.2168.
实施例13
【化合物13】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.22(d,J=8.1Hz,1H),8.04-7.99(m,1H),7.91-7.86(m,1H),7.77-7.65(m,3H),7.51(td,J=7.9,1.5Hz,1H),6.78(d,J=16.5Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.75(m,3H),1.76(s,1H),1.73-1.63(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,166.98,151.40,150.89,149.62,139.63,136.44,134.41,129.85,128.70,128.62,127.38,126.85,121.10,120.28,118.55,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C32H34NO6[M+H]+528.2381,found 528.2385.
实施例14
【化合物14】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.38(dd,J=3.7,2.2Hz,1H),7.81(ddd,J=7.7,2.2,0.7Hz,1H),7.75-7.68(m,1H),7.40(dd,J=7.7,3.7Hz,1H),6.41(d,J=16.8Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,166.64,151.40,148.45,141.00,140.53,134.49,134.41,130.77,127.38,122.48,119.95,118.55,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H31BrNO6[M+H]+556.1329,found 556.1135.
实施例15
【化合物15】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.73(d,J=2.1Hz,1H),7.91-7.84(m,1H),7.65(dt,J=16.9,0.6Hz,1H),7.15(t,J=8.0Hz,1H),6.41(d,J=16.9Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,167.29,164.43,162.42,151.40,150.49,150.38,142.75,137.28,137.21,134.41,128.73,128.71,127.38,118.55,117.23,110.93,110.77,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H31FNO6[M+H]+496.2130,found 496.2131.
实施例16
【化合物16】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ8.53(d,J=2.2Hz,1H),7.91-7.85(m,1H),7.66(d,J=17.1Hz,1H),7.00(d,J=8.1Hz,1H),6.41(d,J=16.8Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.90(s,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.93(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.77(m,1H),1.80-1.74(m,3H),1.73-1.63(m,1H),1.10(s,2H),1.07(s,2H).13CNMR(75MHz,CDCl3)δ208.06,167.29,164.45,151.40,149.04,142.65,136.56,134.41,127.38,125.41,118.55,117.23,110.98,99.28,77.55,73.33,65.38,61.26,57.48,54.53,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd forC29H34FNO7[M+H]+508.2330,found 508.2336.
实施例17
【化合物17】
参照实施例1中化合物1的合成方法。1H NMR(300MHz,CDCl3)δ7.75(dd,J=16.5,0.7Hz,1H),7.63(dt,J=7.7,0.9Hz,1H),7.43(t,J=7.6Hz,1H),7.30(dd,J=7.5,1.3Hz,1H),6.80(d,J=16.5Hz,1H),5.94(dt,J=8.0,1.6Hz,1H),5.74(dd,J=3.3,2.0Hz,1H),5.67(dd,J=3.2,1.9Hz,1H),5.47(dt,J=8.2,5.1Hz,1H),5.40(dd,J=5.5,3.8Hz,1H),4.55(s,1H),4.23(d,J=5.1Hz,1H),4.06-3.98(m,2H),3.84(d,J=12.5Hz,1H),3.17(tq,J=5.9,3.2,2.7Hz,1H),2.61-2.54(m,1H),2.02-1.92(m,1H),1.86(ddd,J=8.2,2.6,1.8Hz,1H),1.83-1.74(m,4H),1.73-1.62(m,1H),1.10(s,2H),1.07(s,2H);13C NMR(75MHz,CDCl3)δ208.06,166.98,152.53,151.40,142.40,139.29,138.29,134.41,127.38,127.31,122.21,120.40,118.55,99.28,77.55,73.33,65.38,61.26,57.48,49.51,44.81,40.41,40.27,32.99,30.97,30.69,26.44,18.49.HR-MS(ESI)m/z:calcd for C28H31BrNO6[M+H]+556.1329,found 556.1334.
实施例18
取上述配方,用常规方法制备成片剂。
药理试验证明,本发明的新型冬凌草急速衍生物具有抗肿瘤作用,可以用于制备抗肿瘤药物。优选治疗的肿瘤疾病是三阴乳腺癌;相对应的用于药理试验的肿瘤细胞株为DU4475细胞株。
下面是本发明部分化合物的药理实验结果:
部分化合物对三阴乳腺癌细胞生长的影响
实验设备与试剂
仪器超净工作台(苏州艾可林净化设备有限公司)
恒温CO2培养箱(日本SANYO)
酶联免疫检测仪(美国BIO-RAD)
倒置生物显微镜(日本OLYMPUS)
试剂青、链霉素混合液(南京凯基生物科技发展有限公司)
胰蛋白酶消化液(南京凯基生物科技发展有限公司)
PBS(南京凯基生物科技发展有限公司)
MTT(BIOSHARP)
DMSO(SIGMA)
细胞株
人三阴乳腺癌细胞DU4475
实验方法
1.细胞消化、计数、制成浓度为5×104个/mL的细胞悬液,96孔板中每孔加入100ul细胞悬液(每孔5×103个细胞);
2. 96孔板置于37℃,5%CO2培养箱中培养24小时;
3.用完全培养基稀释药物至所需浓度,每孔加入100μL相应的含药培养基,同时设立阴性对照组,溶媒对照组,阳性对照组;
4. 96孔板置于37℃,5%CO2培养箱中培养72h;
5.将96孔板进行MTT染色,;λ=490nm,测定OD值。
1)每孔加入20μL MTT(5mg/mL),在培养箱继续培养4小时;
2)弃去培养基,每孔加入150μL DMSO溶解,摇床10分钟轻轻混匀;λ=490nm,酶标仪读出每孔的OD值,计算抑制率。
细胞抑制率%=100%×(阴性对照组OD值-化合物组O D值)/阴性对照组OD值
化合物对人类癌细胞生长影响的实验结果
表1.部分化合物对体外人类三阴乳腺癌细胞生长的影响(IC50:单位μmol/ml)
部分化合物对体内肿瘤生长的影响:
选取体重为18-22g并成功接种三阴乳腺癌细胞DU4475细胞的雌性ICR小鼠(来自上海思捷实验动物中心),随机分组,每组8只。其中一组为空白对照,注射同样给药体积的生理盐水溶液;另一组为阳性药对照组,给予6mg/kg的紫杉醇(购自四川太极制药有限公司,货号为17100021);剩余的组别分别给予25mg/kg剂量的化合物。紫杉醇及上述化合物的溶解溶剂为DMF∶吐温80∶5%生理盐水=10∶2∶88(V∶V∶V),给药方式为1天给药一次,连续给药21天。实验结束后,处死老鼠并手术剥离肿瘤称重。得到的数据用SPSS 17.0进行统计分析。
表2.部分化合物体内抑制肿瘤生长的结果:
组别 | 药物 | 剂量 | 抑瘤率 |
1 | 生理盐水 | - | - |
2 | 化合物1 | 25mg/kg | 70.4% |
3 | 化合物3 | 25mg/kg | 78.6% |
4 | 化合物4 | 25mg/kg | 76.2% |
5 | 化合物7 | 25mg/kg | 64.1% |
6 | 化合物9 | 25mg/kg | 73.5% |
7 | 化合物15 | 25mg/kg | 70.5% |
8 | 冬凌草甲素 | 25mg/kg | 55.9% |
9 | 紫杉醇 | 6mg/kg | 69.0% |
结果发现,紫杉醇给药的小鼠,体重减轻严重,脏器与组织器官切片后发现,毒性较大,而与之相比,冬凌草甲素衍生物均表现毒性较小。
Claims (4)
1.一种消除冬凌草甲素1位羟基的衍生物或其可药用盐,结构如下:
所述L为-CH2CH2-、-CH2CH2CH2-或-CH=CH-;
R为未被取代或被1个取代基所取代的吡啶以及未被取代的吲哚,喹啉,嘧啶,呋喃,噻吩,吡咯,1,3-苯并间二氧杂环戊烯;
其中,所述吡啶任选地被选自下组的取代基取代:卤素、C1-C6烷氧基。
2.根据权利要求1所述的消除冬凌草甲素1位羟基的衍生物或其可药用盐,为如下任一种:
3.一种药物组合物,其含有治疗有效量的一种或多种如权利要求1-2中任一项所述的消除冬凌草甲素1位羟基的衍生物或其可药用盐及药学上可接受的载体或辅料。
4.权利要求1-2任一项所述的消除冬凌草甲素1位羟基的衍生物或其可药用盐在制备治疗三阴乳腺癌药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210083027.6A CN114478566B (zh) | 2022-01-24 | 2022-01-24 | 消除冬凌草甲素1位羟基的衍生物及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210083027.6A CN114478566B (zh) | 2022-01-24 | 2022-01-24 | 消除冬凌草甲素1位羟基的衍生物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114478566A CN114478566A (zh) | 2022-05-13 |
CN114478566B true CN114478566B (zh) | 2023-08-22 |
Family
ID=81474811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210083027.6A Active CN114478566B (zh) | 2022-01-24 | 2022-01-24 | 消除冬凌草甲素1位羟基的衍生物及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114478566B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165841A1 (en) * | 2013-04-05 | 2014-10-09 | The Board Of Regents Of The University Of Texas System | Oridonin analogs, compositions, and methods related thereto |
CN106749305A (zh) * | 2016-11-16 | 2017-05-31 | 中国药科大学 | A-环改造的冬凌草甲素衍生物、其制备方法及用途 |
-
2022
- 2022-01-24 CN CN202210083027.6A patent/CN114478566B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165841A1 (en) * | 2013-04-05 | 2014-10-09 | The Board Of Regents Of The University Of Texas System | Oridonin analogs, compositions, and methods related thereto |
CN106749305A (zh) * | 2016-11-16 | 2017-05-31 | 中国药科大学 | A-环改造的冬凌草甲素衍生物、其制备方法及用途 |
Non-Patent Citations (1)
Title |
---|
孟繁浩.药物化学.2016,第386页,表23-1. * |
Also Published As
Publication number | Publication date |
---|---|
CN114478566A (zh) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007082475A1 (fr) | Nouveau composé diterpène ent-kaurène et ses dérivés, leur préparation et leur utilisation | |
CN111471080B (zh) | ocotillol型人参皂苷元A环并氨基噻唑环衍生物及制备方法 | |
EP2233467B1 (en) | Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof | |
CN110981882B (zh) | 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途 | |
CN114478566B (zh) | 消除冬凌草甲素1位羟基的衍生物及用途 | |
CN113698415A (zh) | 一种新型的冬凌草甲素类似物及衍生物、其制备方法及医药用途 | |
CN115260053A (zh) | 一种具有抗肿瘤活性的化合物及其制备方法与它的用途 | |
CN104530081A (zh) | 雷帕霉素的氮杂环衍生物和用途 | |
CN109503697B (zh) | 3-(l-苯丙氨酸)-五环三萜衍生物及其合成方法和应用 | |
CN114380780B (zh) | 一种新型的长栲利素a衍生物、其制备方法及医药用途 | |
CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 | |
CN111777577A (zh) | 一类紫杉醇衍生物及其在制备防治人恶性肿瘤药物中的用途 | |
CN114702506B (zh) | 11-羰基-20-乙氧基济源冬凌草甲素及其14-oh酯化系列衍生物和用途 | |
CN114437102B (zh) | 一种新型的冬凌草甲素去6位羟基衍生物、其制备方法及医药用途 | |
CN115109083B (zh) | Pyridostatin类化合物及其制备方法、应用、药物组合物 | |
CN109517025B (zh) | 28-(l-苯丙氨酸)-五环三萜衍生物及其合成方法和应用 | |
CN115010642B (zh) | β-榄香烯酰亚胺类衍生物及其应用 | |
CN115057850B (zh) | 一种芦荟大黄素衍生物及其制备方法和应用 | |
CN110759961A (zh) | 一类熊果酸吲哚醌酰胺衍生物及其制备方法和应用 | |
CN116715706B (zh) | 一种延长茶氨酸体内半衰期的化学修饰方法 | |
CN113788809B (zh) | 一类色原酮的3位拼合氮芥衍生物与应用 | |
CN115677812B (zh) | 一类雷公藤红素衍生物及其制备方法与应用 | |
CN108383838B (zh) | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 | |
CN108456207B (zh) | 一种酰胺类衍生物及其在心脑血管方面的应用 | |
CN116041362A (zh) | Aurovertin B衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |